HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Based on phase II data demonstrating long-term remission in 35% of heavily pretreated patients, HDAC inhibitors have been approved by the US Food and Drug Administration for second-line treatment of CTCL [16,17].